Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by unevenon Nov 14, 2009 12:50am
771 Views
Post# 16486598

RE: THE NEXT PRE !

RE: THE NEXT PRE !Whoo there... a bit of work to be done before drilling... read the release...

Llano 27 block totals 16,470 hectares and it is surrounded by producing oil and gas fields (including La Punta, Entrerrios, Santiago and Estero), and is on strike with the La Punta block 2244 oil field which has historic production of over 3.7 million barrels of oil and total recoverable field reserves estimated between six million and nine million barrels of oil and July, 2009, production rate in excess of 3,600 barrels of oil per day of 34-degree API oil from two wells (Ministerio de Minas Y Energia, Forma 9). Work commitments over the first 36-month phase total approximately $6.48-million (U.S.) and includes completion of 144 kilometres of 2-D seismic and the drilling of an exploratory well.

Llanos 36 block totals 33,356 hectares and it is also offset by producing fields (including Chichimene, Apiay and Castilla) and oil and gas infrastructure, including pipelines and roads. Work commitments of the first 36-month phase total $5.5-million (U.S.) and includes completion of 93 km of 2-D seismic and the drilling of an exploratory well.

Llanos 21 block totals 7,108 hectares and is offset by several oil fields. Work commitments of the first 36-month phase total approximately $7-million (U.S.) and includes 20 km of 2-D seismic and 50 square km of 3-D seismic, and the drilling of two exploratory wells.

Bullboard Posts